https://padlet.com/csalas21/y5hec5w6oxm0 The first Long-acting Drug-eluting Vascular Stent en-us 2018-10-02 23:21:51 UTC 2018-10-03 00:03:25 UTC hello@padlet.com csalas21 https://padlet.com/csalas21/y5hec5w6oxm0/wish/288408702 The Eluvia drug-eluting vascular stent designed by Boston Scientific is now FDA approved in the U.S. This stent is one of the 1st peripheral disease stents to have sustained release of paclitarel, an anti proliferative drug for as long as a year. The SFA is known for restenosis and this stent has shown a drastic lower rate in restenosis in the SFA for up to a year. The Eluvia stent was approved by the FDA after the "imperial" study which was co-lead by William Grey, M.D. (Medgadget, 2018]]> 2018-10-02 23:24:57 UTC https://padlet.com/csalas21/y5hec5w6oxm0/wish/288408702 csalas21 https://padlet.com/csalas21/y5hec5w6oxm0/wish/288409983 I believe the Eluvia stent is an amazing device. The fact that patients will be able to go longer without restenosis and live pain free from peripheral disease is wonderful. As a former cardiac nurse I cannot tell you how many times interventions would be redone on a patient within 3 months due to restenosis even with the patient taking their medicines and changing life-style. ]]> 2018-10-02 23:36:12 UTC https://padlet.com/csalas21/y5hec5w6oxm0/wish/288409983 csalas21 https://padlet.com/csalas21/y5hec5w6oxm0/wish/288410327 1. Eluvia stent gives a smaller bolus of the initial medicine and then levels out to last and release for over 12 months.
2. Patient has up to 1 year for potential restenosis.
3. The patient doesn't have to have as many re-vascularization procedures for patient to be pain free and able to walk.  ]]> 2018-10-02 23:39:01 UTC https://padlet.com/csalas21/y5hec5w6oxm0/wish/288410327 csalas21 https://padlet.com/csalas21/y5hec5w6oxm0/wish/288410728 1. Eluvia stent is only for peripheral disease at this time.
2. What will the cost be for patients?
3. Patient still has to take anti-platelet drugs.]]> 2018-10-02 23:42:09 UTC https://padlet.com/csalas21/y5hec5w6oxm0/wish/288410728 csalas21 https://padlet.com/csalas21/y5hec5w6oxm0/wish/288411067 For my evaluation team I choose Daisy, Carter, Pablo, Daniel, and Shelia.
Daisy-Developer: I choose Daisy because she could develop great ideas on how to evaluate our innovation.
Carter- Communication: I choose Carter because he can make sure one as a team we are all on the same page, and two he can make sure we communicate all important points on our innovation.
Pablo- Positivity: I choose Pablo to keep the team on a positive note and to keep working.
Daniel- Focus: I choose Daniel because he can also keep the whole team on task and working.
Shelia- Strategic: I choose Shelia because she can help the team be strategic when working on the innovation.]]> 2018-10-02 23:44:38 UTC https://padlet.com/csalas21/y5hec5w6oxm0/wish/288411067 csalas21 https://padlet.com/csalas21/y5hec5w6oxm0/wish/288411658 Medgadget. (2018, September 27). Boston Scientific's Eluvia Peripheral Long Term Drug Eulting Stent FDA Approved. Retrieved from Medgadget: https://www.medgadget.com/2018/09/boston-scientifics-eluvia-peripheral-long-term-drug-eluting-stent-fda-approved.html]]> 2018-10-02 23:49:44 UTC https://padlet.com/csalas21/y5hec5w6oxm0/wish/288411658 csalas21 https://padlet.com/csalas21/y5hec5w6oxm0/wish/288412463 Eluvia Stent]]> 2018-10-02 23:57:09 UTC https://padlet.com/csalas21/y5hec5w6oxm0/wish/288412463